Reducing antimicrobial resistance: accelerated efforts are needed to meet the EU targets

The European Commission on Drugs and Cosmetics (ECDC) has reported that the EU is falling short of its 2030 antimicrobial resistance (AMR) targets, with antibiotic consumption increasing by 1% between 2019 and 2023. While there have been some reductions in methicillin-resistant Staphylococcus aureus bloodstream infections, the incidence of carbapenem-resistant Klebsiella pneumoniae bloodstream infections has increased by almost 60%. This poses a growing threat to patients in hospitals across the EU, as few therapeutic options remain for treating carbapenem-resistant K. pneumoniae. ECDC Director Dr Pamela Rendi-Wagner emphasizes the need for a united, urgent response across the EU to prevent AMR from undermining healthcare and sustaining the effectiveness of antibiotics for future generations. The ECDC is calling for accelerated efforts in infection prevention and control, prudent use of antimicrobials, and the development of and access to novel antimicrobials. Without stronger public health action, the EU may not reach all its targets by 2030, leading to more difficult-to-treat infections and AMR-related deaths.